

JUL 30 2001

SHEET 2 OF 2

FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. RIORD.006A	APPLICATION NO. 09/781,023
	APPLICANT Riordan, N.	
	FILING DATE February 9, 2001	GROUP Unknown

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
NAD	Donald L. Morton et al., <i>Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine</i> , Ann. Surg., October 1992, pp. 463-482.
	N.S. Rote et al., <i>Determination of Incidence and Partial Characterization of Tumor-Associated Antigens Found in the Urine of Patients Bearing Solid Tumors</i> , Int. J. Cancer, Vol. 26, 1980, pp. 203-210.
	Sanford J. Finck et al., <i>Excretion of Tumor-Associated Antigen(s) in the Urine of Patients With Colon Carcinoma</i> , Journal of Surgical Oncology, Vol. 21, 1982, pp. 81-86.
	David M. Euhus et al., <i>Detection of a Tumor-Associated Glycoprotein Antigen in Serum and Urine of Melanoma Patients by Murine Monoclonal Antibody (AD1-40F4) in Enzyme Immunoassay</i> , Journal of Clinical Laboratory Analysis, Vol. 3, 1989, pp. 184-190.
	Ralph W. DeVere et al., <i>Urinary Prostate Specific Antigen Levels: Role in Monitoring the Response of Prostate Cancer to Therapy</i> , The Journal of Urology, Vol. 147, March 1992, pp. 947-951.
	P. Cariuk et al., <i>Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients</i> , British Journal of Cancer, Vol. 76, No. 5, 1997, pp. 606-613.
	Franz Halberg et al., <i>Cancer Marker Assessment: Case Report on Salivary and Urinary CEA, in vivo</i> , Vol. 9, 1995, pp. 311-314.

H:\DOCS\JAH\JAH-4655.DOC:bb  
071301

EXAMINER <i>N. Adams</i>	DATE CONSIDERED <i>4-3-02</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RIORD.006AAPPLICATION NO.  
09/781,023


RECEIVED

AUG 03 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Riordan, N.FILING DATE  
February 9, 2001GROUP  
Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

## OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
VAD	Rajender K. Chawla et al., <i>Isolation and Characterization of a Glycoprotein (JBB5) in the Urine of a Patient with Carcinoma of the Colon</i> , <u>CANCER RESEARCH</u> , Vol. 37, March 1977, pp. 873-878.
	Peter A. Cohen et al., <i>CD4* T-Cells from Mice Immunized to Syngeneic Sarcomas Recognize Distinct, Non-Shared Tumor Antigens</i> , <u>CANCER RESEARCH</u> , Vol. 54, February 15, 1994, pp. 1055-1058.
	Frank J. Hsu et al., <i>Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells</i> , <u>NATURE MEDICINE</u> , Vol. 2, No. 1, January 1996, pp. 52-58.
	G. Murphy et al., <i>Phase I Clinical Trial: T-Cell Therapy for Prostate Cancer Using Autologous Dendritic Cells Pulsed With HLA-A02011-Specific Peptides from Prostate-Specific Membrane Antigen</i> , <u>The Prostate</u> , Vol. 29, 1996, pp. 371-380.
	Frank O. Nestle et al., <i>Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells</i> , <u>NATURE MEDICINE</u> , Vol. 4, No. 3, March 1998, pp. 328-332.

EXAMINER

N. J. Riordan

DATE CONSIDERED

4-3-02

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.